Search the Newsreel

4% Undervalued? Halozyme Therapeutics (HALO) Nears Earnings At A Record High

Halozyme Therapeutics (HALO) has reached a record high ahead of its earnings release, with a 3-year shareholder return of 94.35%. While its valuation is considered 4.2% undervalued by some at $86.89 due to expanding partnerships and new product launches, its P/E ratio of 28.3x …

Is Halozyme Therapeutics (HALO) Fully Valued After Its 107% Gain?

Halozyme Therapeutics (HALO) has seen a significant 107.1% return over the past five years, but its current P/E ratio of 28.4x suggests it may be overvalued compared to its tailored fair P/E of 20.0x and the biotech industry average. While recent collaborations and the …

Precision Trading with Halozyme Therapeutics Inc. (HALO) Risk Zones

This article provides a detailed analysis of Halozyme Therapeutics Inc. (HALO) using AI models to identify potential trading strategies and risk zones. It highlights strong near and mid-term sentiment, compelling upside potential due to a lack of resistance levels above the current price, and …

Zymeworks (ZYME) to Announce Earnings on Thursday

Halozyme Therapeutics Inc (HALO) Institutional Confidence

Halozyme Therapeutics Inc (HALO) has a strong institutional confidence score of 10.00, ranking 1st in the Pharmaceuticals industry. The institutional shareholding proportion increased by 10.45% quarter-over-quarter to 117.14%. Bill Nygren from OAKMX is the largest institutional shareholder, holding 703.13K shares, a 186.36% increase in …

This Medical Technology Stock Claws Back To A Buy Zone

This medical technology name has a patented method of drug delivery. Halozyme stock recently hit a record high with earnings due out soon. Continue Reading

ETFs Investing in Halozyme Therapeutics, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Halozyme Therapeutics, Inc. The ETFs are sorted by their market value of Halozyme stocks and include details such as weight, issuer, management style, expense ratio, assets under management (AUM), price, change, and …

Q1 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks

Q1 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks As the craze of earnings season draws to a close, here's a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at …

EXOZ|eXoZymes Inc|Price:4.500|Chg%:-0.210

eXoZymes Inc, formerly Invizyne Technologies, Inc., is an artificial intelligence (AI) engineered enzyme company that transforms sustainable feedstock into essential chemicals, medicines, and biofuels. The company uses AI to create advanced enzymes that operate in bioreactors, offering a sustainable alternative to traditional chemical production. …

Biotech Stocks At 52-Week Highs- IKT, HALO, JAZZ, CORT, LQDA

(RTTNews) - The following biotech stocks reached 52-week highs on July 24, 2026, driven by key catalysts like the upcoming release of quarterly reports or various regulatory milestones. Inhibikase Therapeutics Inc. (IKT) Inhikibase Therapeutics is a clinical-stage pharmaceutical company specializing in developing therapies for …

HALO|Halozyme Therapeutics Inc|Price:81.930|Chg%:+1.090

Halozyme Therapeutics Inc. (HALO) is a biopharmaceutical company focused on improving patient experiences through its ENHANZE drug delivery technology, which facilitates subcutaneous drug delivery. The company licenses this technology to partners and develops its own drug-device combination products like Hylenex and XYOSTED. The article …

eXoZymes Inc. Revenue Breakdown – NASDAQ:EXOZ

Halozyme Therapeutics (HALO) Q4 2024 Earnings Report - Results, Call & Slides

Halozyme Therapeutics (HALO) has released its Q4 2024 earnings report, surpassing analyst expectations for both EPS and revenue. The company reported actual EPS of $22.06 against a consensus of $20.28, and actual revenue of $5.22 billion exceeding the expected $5.00 billion. The next earnings …

Halozyme Therapeutics Inc (HALO) Income Statement

This article presents the quarterly and annual income statements for Halozyme Therapeutics Inc (HALO), offering detailed financial insights into the company's performance, including revenue, expenses, and net income figures across various fiscal periods. It also provides an FAQ section explaining how to read the …

Halozyme Therapeutics, Inc. Revenue Breakdown – BX:RV7

This article provides a revenue breakdown for Halozyme Therapeutics, Inc. (BX:RV7), highlighting that the company generated 1.11 billion CHF last year, primarily from its Proprietary Enzymes, Devices, Hypercon Technology, and Surf Bio Technology segment. The United States was the largest contributor to this revenue, …

Halozyme Therapeutics Market Sentiment

This article provides an overview of Halozyme Therapeutics (HALO) market sentiment, including analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from analysts with a significant number of calls over puts, but also notes rising short interest and recent …

HALO5638653 Bond Risk Profile

This article provides a risk profile for the Halozyme Therapeutics, Inc. bond, HALO5638653, with a 1.0% coupon rate and maturity on August 15, 2028. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors evaluate …

HALO5638653 Bond Profile — Key Metrics

This article provides key metrics for the HALO5638653 bond issued by Halozyme Therapeutics, Inc. The bond has a 1.0% coupon rate and matures on August 15, 2028, with an outstanding amount of $470 million. Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company focused …

Halozyme Therapeutics stock hits all-time high at 82.42 USD

Halozyme Therapeutics Inc. (HALO) stock reached an all-time high of $82.42, reflecting a 37.55% growth over the past year. InvestingPro analysis suggests the stock is undervalued, indicating potential for further upside. Recent company developments include a collaboration with Incyte Pharmaceuticals and leadership changes, with …

Halozyme to host Aug. 6 call on second-quarter results

Halozyme (Nasdaq: HALO) announced it will release its second quarter 2026 financial and operating results on Thursday, August 6, 2026, after the U.S. market close. The company will host a conference call on the same day at 1:30 p.m. PT / 4:30 p.m. ET …

HALO: Future Upside Will Rely On Expanding ENHANZE Drug Delivery Partnerships

Halozyme Therapeutics' fair value has been modestly increased to $86.89 per share due to updated assumptions around revenue growth and profitability, with analysts presenting mixed but focused views. Key developments include new partnerships with Incyte and GSK for its ENHANZE technology, positive clinical trial …

Halozyme to Report Second Quarter 2026 Financial and Operating Results

Halozyme Therapeutics, Inc. (Nasdaq: HALO) will announce its second quarter 2026 financial and operating results on Thursday, August 6, 2026, after market close. The company will also host a conference call on the same day at 1:30 PM PT/4:30 PM ET to discuss these …

Halozyme Therapeutics to report Q2 2026 results on August 6

Halozyme Therapeutics announced that it will release its second quarter 2026 financial and operating results on Thursday, August 6, 2026, after the close of trading. The company will host a conference call on the same day to discuss the results and provide stakeholders with …

Should Halozyme’s New ENHANZE–Incyte Oncology Pact Reshape How HALO Investors View Its Royalty Model?

Halozyme Therapeutics announced a new global collaboration with Incyte, leveraging its ENHANZE drug delivery technology for an oncology program. This partnership aims to broaden Halozyme's royalty streams in blood cancers, adding to its existing collaborations. While this new deal reinforces Halozyme's strategy of expanding …

FUL or NVZMY: Which Is the Better Value Stock Right Now?

Investors interested in Chemical - Specialty stocks are likely familiar with H. B. Fuller (FUL) and Novozymes A/S (NVZMY). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. The best way …

Halozyme’s Partnerships, Earnings Growth See Shares Near All-Time Highs

Halozyme Therapeutics, Inc. (HALO) shares have seen significant gains, rising 539% since March 2014 and 52% this year, driven by strong institutional buying and robust fundamentals. The company's recent earnings report showed record revenue and a raised 2026 guidance, indicating continued growth prospects for …

Did Halozyme’s (HALO) New Incyte Enhanze Deal Just Redefine Its Precision Oncology Royalty Engine?

Halozyme Therapeutics recently entered a global partnership and licence agreement with Incyte to apply its Enhanze drug delivery technology to additional subcutaneous formulations of INCA033989, a monoclonal antibody targeting mutant calreticulin in myeloproliferative neoplasms. This collaboration highlights how Halozyme can plug its Enhanze platform …

Benchmark reiterates Halozyme stock Buy rating on Incyte deal By Investing.com

Benchmark reiterated its Buy rating and $90 price target for Halozyme Therapeutics following the company's licensing agreement with Incyte Pharmaceuticals. The deal involves Halozyme's Enhanze drug development technology to create subcutaneous formulations of Incyte's INCA033989. Halozyme will receive an upfront payment, potential development milestones, …

Halozyme Therapeutics (HALO) Lands Incyte Deal On A Valuation That Still Looks Undervalued

Halozyme Therapeutics recently partnered with Incyte, using its Enhanze technology for subcutaneous formulations. Despite a 12.46% share price increase over 30 days and long-term gains, the stock appears undervalued, with analysts estimating a fair value of $83.90 compared to its current $77.09. However, its …

Halozyme in deal with Incyte to use Enhanze technology for neoplasms candidate

[Businessmen shaking hands] Andy Andrews * Halozyme (HALO [https://seekingalpha.com/symbol/HALO]) has signed a global collaboration and license agreement with Incyte (INCY [https://seekingalpha.com/symbol/INCY]) to potentially use the former's Enhanze drug delivery technology with the latter's INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody for mutCALR-expressing myeloproliferative …

Halozyme partners with Incyte on drug delivery technology By Investing.com

Halozyme Therapeutics Inc. has announced a global collaboration and license agreement with Incyte to develop subcutaneous formulations of INCA033989 using Halozyme's ENHANZE drug delivery technology. Halozyme will receive an upfront payment and is eligible for additional milestone payments and royalties. The partnership aims to …

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

Halozyme Therapeutics, Inc. (Nasdaq: HALO) has entered into a global collaboration and license agreement with Incyte (Nasdaq: INCY) to develop subcutaneous formulations of INCA033989 using Halozyme's ENHANZE® drug delivery technology. This collaboration aims to improve the treatment experience for patients with mutCALR-expressing myeloproliferative neoplasms …

Income Investors Should Know That Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Goes Ex-Dividend Soon

Technical Reactions to HALO Trends in Macro Strategies

This article from Stock Traders Daily discusses technical reactions to HALO trends in macro strategies, focusing on Halozyme Therapeutics Inc. (NASDAQ: HALO). It highlights conflicting sentiment across different time horizons, suggesting choppy market conditions for the stock. The analysis provides specific trading strategies (Position, …

Halozyme Therapeutics (HALO) Gets A Lift As Darzalex Faspro Trial Improves Survival

Halozyme Therapeutics (HALO) saw a positive impact from a partner trial for Darzalex Faspro, which uses Halozyme's ENHANZE technology. The trial reported significant survival benefits for multiple myeloma patients, highlighting the value of ENHANZE in improving established cancer therapies. This success reinforces Halozyme's business …

Advanced Enzyme fixes July 24 record date for ₹1.35 dividend